Stereotactic ablative radiotherapy delivered by image-guided helical tomotherapy for extracranial oligometastases

Sole, Claudio V.; Guerra, J.L. Lopez; Matute, R.; Jaen, J.; Puebla, F.; Rivin, E.; Sánchez-Reyes, A.; Beltran, C.; Bourgier, C.; Marsiglia, H.

doi:10.1007/s12094-012-0956-2

Cited by 10 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So, the application of MVCT can catch the change of tumor volume to achieve adaptive radiotherapy (31). Previous studies also confirmed the safety and effectiveness of tomotherapy for SBRT (32)(33)(34).…”

Section: Discussionsupporting

confidence: 54%

Dosimetric comparison of helical tomotherapy and conventional Linac-based X-knife stereotactic body radiation therapy for primary lung cancer or pulmonary metastases

Li¹,

Yang²,

Liu³

et al. 2018

J. Thorac. Dis.

View full text Add to dashboard Cite

Background: To compare helical tomotherapy (HT) with X-knife stereotactic body radiation therapy (HT-SBRT/X-SBRT) for primary or metastatic lung cancer regarding planning target volume (PTV) coverage, such as homogeneity index (HI), conformity index (CI) and dose-volume histogram (DVH) of organs at risk (OARs). Methods:We retrospectively analyzed 21 patients receiving definitive radiation treatment for non-small cell lung cancer (NSCLC) or pulmonary metastases at our institution between March 2015 and October 2016.Tumors were irradiated with 4-10 Gy per fraction in 5-15 fractions. Plans were compared according to PTV coverage and OARs sparing.Results: Significant differences between HT and X-knife were observed for both HI (P=0.003) and CI (P<0.001). The V5 (P=0.001), V10 (P=0.009), V20 (P=0.001), the mean lung dose (P=0.005) of total lung and maximum dose of the spinal cord (P=0.010) were significantly lower in the X-SBRT group than the HT-SBRT group. There were no significant differences for the V30 (P=0.075) and the mean heart dose (P=0.584) between the two groups.Conclusions: X-SBRT was dosimetrically superior to HT-SBRT, when applied in these tumors' maximum diameters <5 cm. As HT resulted in increased low-dose volume, it is essential to optimize the patient selection in order to avoid severe radiation pneumonitis in HT-SBRT.

show abstract

Section: Discussionsupporting

confidence: 54%

Dosimetric comparison of helical tomotherapy and conventional Linac-based X-knife stereotactic body radiation therapy for primary lung cancer or pulmonary metastases

Li¹,

Yang²,

Liu³

et al. 2018

J. Thorac. Dis.

View full text Add to dashboard Cite

show abstract

“…Owing to the aforementioned disadvantages of HT compared with other stereotactic treatments in this setting, HTT is slow to be adopted in clinical practice, and few studies-often evaluating small series of patients with inhomogeneous characteristics and short FU-are available in the recent literature [9][10][11][12][13][14][15][16] (Table 4). Several points can be gleaned from this study, which to our knowledge is one among the largest series addressing the use of HTT in the treatment of lung lesions.…”

Section: Discussionmentioning

confidence: 99%

“…5,6 While dosimetric findings have shown that such capabilities can potentially translate into the delivery of an increased tumour dose with doses to normal tissues decreased compared with other techniques, 7,8 only a limited number of patients were included in recent studies that have addressed the feasibility of hypofractionated or ablative radiotherapy (RT) regimens for lung tumours treated with HT. [9][10][11][12][13][14][15][16] Reasonable arguments might be advocated for its slow adoption in the clinical practice in this setting: during HT it is not only the tumour and the MLC that are moving but also the radiation source and couch, which can maximize the breathing interplay effect (i.e. difference between planned and delivered absorbed doses that arises from a mismatch between the tumour and the MLC because of motion).…”

Section: Introductionmentioning

confidence: 99%

Treatment outcomes and patterns of radiologic appearance after hypofractionated image-guided radiotherapy delivered with helical tomotherapy (HHT) for lung tumours

Arcangeli

Falcinelli²,

Bracci

et al. 2017

The British Journal of Radiology

View full text Add to dashboard Cite

Cite this article as: Arcangeli S, Falcinelli L, Bracci S, Greco A, Monaco A, Dognini J, et al. Treatment outcomes and patterns of radiologic appearance after hypofractionated image-guided radiotherapy delivered with helical tomotherapy (HHT) for lung tumours. Objective: To evaluate treatment outcomes and patterns of CT lung injury after hypofractionated image-guided radiotherapy delivered with helical tomotherapy (HHT) in a series of inoperable lung lesions. Methods: 68 patients who were medically inoperable (69 lesions) without evidence of viable extrathoracic disease were included. Dose prescription was driven by tumour location (hilar/pericentral vs peripheral) and/or target volume.

show abstract

“…Zhang et al reported that a disease-free interval of more than 12 months was significantly related to longer OS in patients with lung metastases who received SBRT [33]. Furthermore, other researchers have reported that a longer disease-free interval was significantly associated with longer OS in patients with extracranial oligo-recurrence or recurrent hepatocellular carcinoma following SBRT [34, 35]. These results, as well as those of our study, indicate that C-ion RT should be considered in patients with LN oligo-recurrence, particularly in patients with a longer disease-free interval.…”

Section: Discussionmentioning

confidence: 99%

Carbon-ion radiotherapy for lymph node oligo-recurrence: a multi-institutional study by the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS)

et al. 2019

View full text Add to dashboard Cite

Background The efficacy of carbon-ion radiotherapy (C-ion RT) for lymph node (LN) oligo-recurrence has only been evaluated in limited single-center studies. We aimed to investigate the benefit of C-ion RT for LN oligo-recurrence in a large multi-center study. Methods Patients who received C-ion RT between December 1996 and December 2015 at 4 participating facilities and who met the following eligibility criteria were included: (i) histological or clinical diagnosis of LN recurrence; (ii) controlled primary lesion; (iii) no recurrence other than LN; (iv) LN recurrence involved in a single lymphatic site; and (v) age ≥ 20 years. Results A total of 323 patients were enrolled. Median follow-up period was 34 months for surviving patients. The most common dose fractionation of C-ion RT was 48.0 Gy (relative biological effectiveness) in 12 fractions. Forty-seven patients had a history of RT at the recurrent site. The 2-year local control (LC) and overall survival (OS) rates after C-ion RT were 85% and 63%, respectively. Only 1 patient developed grade-3 toxicity. Factors such as LN diameter, histology, and history of previous RT did not correlate with LC. Smaller diameters (< 30 mm) and numbers (≤ 3) of LN metastases as well as longer disease-free intervals post-primary therapy (≥ 16 months) were associated with significantly better OS. Conclusions C-ion RT for LN oligo-recurrence appeared to be effective and safe. C-ion RT may provide a survival benefit to patients with LN oligo-recurrence, particularly to those with few LN metastases, smaller LN diameters, and longer disease-free intervals. Electronic supplementary material The online version of this article (10.1007/s10147-019-01440-y) contains supplementary material, which is available to authorized users.

show abstract

Stereotactic ablative radiotherapy delivered by image-guided helical tomotherapy for extracranial oligometastases

Abstract: SABR delivered by image-guided HT is well tolerated and offers adequate LC with low acute morbidity in patients with extracranial oligometastatic disease. We found that the response to HT was the only predictor for OS.

Cited by 10 publications

References 25 publications

Dosimetric comparison of helical tomotherapy and conventional Linac-based X-knife stereotactic body radiation therapy for primary lung cancer or pulmonary metastases

Dosimetric comparison of helical tomotherapy and conventional Linac-based X-knife stereotactic body radiation therapy for primary lung cancer or pulmonary metastases

Treatment outcomes and patterns of radiologic appearance after hypofractionated image-guided radiotherapy delivered with helical tomotherapy (HHT) for lung tumours

Carbon-ion radiotherapy for lymph node oligo-recurrence: a multi-institutional study by the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS)

Contact Info

Product

Resources

About